CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Colon tumors arise in a stepwise fashion from either discrete genetic perturbations or epigenetic dysregulation. To uncover the key epigenetic regulators that drive colon cancer growth, we used a CRISPR loss-of-function screen and identified a number of essential genes, including the bromodomain and extraterminal (BET) protein BRD4. We found that BRD4 is critical for colon cancer proliferation, and its knockdown led to differentiation effects in vivo. JQ1, a BET inhibitor, preferentially reduced growth in a subset of epigenetically dysregulated colon cancers characterized by the CpG island methylator phenotype (CIMP). Integrated transcriptomic and genomic analyses defined a distinct superenhancer in CIMP+ colon cancers that regulates cMYC transcription. We found that the long noncoding RNA colon cancer-associated transcript 1 (CCAT1) is transcribed from this superenhancer and is exquisitely sensitive to BET inhibition. Concordantly, cMYC transcription and cell growth were tightly correlated with the presence of CCAT1 RNA in a variety of tumor types. Taken together, we propose that CCAT1 is a clinically tractable biomarker for identifying patients who are likely to benefit from BET inhibitors.

[1]  Jonathan H. Esensten,et al.  Cdk8 deletion in the ApcMin murine tumour model represses EZH2 activity and accelerates tumourigenesis , 2015, The Journal of pathology.

[2]  B. Jiang,et al.  BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis , 2015, International journal of molecular sciences.

[3]  Alexander Stojadinovic,et al.  Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach , 2015, Journal of Cancer.

[4]  Yan Zhang,et al.  Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p , 2015, Cell Death and Disease.

[5]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[6]  Hiromu Suzuki,et al.  Biological significance of the CpG island methylator phenotype. , 2014, Biochemical and biophysical research communications.

[7]  D. Reinberg,et al.  BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones , 2014, Nature Structural &Molecular Biology.

[8]  R. Young,et al.  An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.

[9]  Jill M Dowen,et al.  Control of Cell Identity Genes Occurs in Insulated Neighborhoods in Mammalian Chromosomes , 2014, Cell.

[10]  L. Altucci,et al.  Epigenetic drugs against cancer: an evolving landscape , 2014, Archives of Toxicology.

[11]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[12]  M. Yaylaoglu,et al.  An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth , 2014, Genes & development.

[13]  J. Rinn,et al.  'Lnc'-ing enhancers to MYC regulation , 2014, Cell Research.

[14]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[15]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[16]  Junhui Ge,et al.  Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus , 2014, Cell Research.

[17]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[18]  S. Baylin,et al.  Harnessing the potential of epigenetic therapy to target solid tumors. , 2014, The Journal of clinical investigation.

[19]  Yilong Li,et al.  Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.

[20]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[21]  P. Bamborough,et al.  Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. , 2013, Journal of medicinal chemistry.

[22]  P. A. Futreal,et al.  Emerging patterns of somatic mutations in cancer , 2013, Nature Reviews Genetics.

[23]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[24]  Anne E Carpenter,et al.  The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling , 2013, Nature.

[25]  B. Cairns,et al.  Epigenetic regulation of colon cancer and intestinal stem cells. , 2013, Current opinion in cell biology.

[26]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[29]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[30]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[31]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[32]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[33]  Melissa E. Ko,et al.  CDX2 is an amplified lineage-survival oncogene in colorectal cancer , 2012, Proceedings of the National Academy of Sciences.

[34]  F. E. Bertrand,et al.  Developmental pathways in colon cancer , 2012, Cell cycle.

[35]  M. Meyerson,et al.  Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. , 2012, Cancer research.

[36]  Tony Kouzarides,et al.  Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.

[37]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[38]  M. Fraga,et al.  Aberrant epigenetic regulation of bromodomain Brd4 in human colon cancer , 2012, Journal of Molecular Medicine.

[39]  Zora Modrusan,et al.  CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. , 2012, Cancer research.

[40]  Jianxin You,et al.  Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-order Chromatin Structure* , 2012, The Journal of Biological Chemistry.

[41]  William M. Grady,et al.  Epigenetics and colorectal cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[42]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[43]  Thomas M. Harris,et al.  Hypermethylation of a cluster of Krüppel-type zinc finger protein genes on chromosome 19q13 in oropharyngeal squamous cell carcinoma. , 2011, The American journal of pathology.

[44]  R. M. Simpson,et al.  Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. , 2011, Cancer research.

[45]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[46]  J. Teo,et al.  The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. , 2010, Advanced drug delivery reviews.

[47]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[48]  Shelby A. Blythe,et al.  beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8 methyltransferase, Prmt2. , 2010, Developmental cell.

[49]  J. Hoheisel,et al.  Pooled RNAi Screens - Technical and Biological Aspects , 2010, Current genomics.

[50]  M. A. van de Wiel,et al.  Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression , 2010, Tumor Biology.

[51]  Robin P Boushey,et al.  Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. , 2009, Clinics in colon and rectal surgery.

[52]  W. Hahn,et al.  Revving the Throttle on an oncogene: CDK8 takes the driver seat. , 2009, Cancer research.

[53]  Qian Tao,et al.  Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers , 2009, Epigenetics.

[54]  D. Notterman,et al.  CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer , 2008, Clinical Cancer Research.

[55]  J. Issa.  Colon Cancer: It's CIN or CIMP , 2008, Clinical Cancer Research.

[56]  E. Liu,et al.  DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. , 2008, Cancer cell.

[57]  K. Ozato,et al.  The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase* , 2008, Journal of Biological Chemistry.

[58]  David P. Davis,et al.  pHUSH: a single vector system for conditional gene expression , 2007, BMC Biotechnology.

[59]  E. Niclas Jonsson,et al.  The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[60]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[61]  Julie A. Wilkins,et al.  Myc deletion rescues Apc deficiency in the small intestine , 2007, Nature.

[62]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[63]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[64]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[65]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[66]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[67]  K. Vermeulen,et al.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.

[68]  S. Baylin.  Mechanisms underlying epigenetically mediated gene silencing in cancer. , 2002, Seminars in cancer biology.

[69]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[70]  C. Dang,et al.  Cancer genetics: Tumor suppressor meets oncogene , 1999, Current Biology.

[71]  E. Fearon.  Molecular Genetics of Colorectal Cancer , 1995, Annals of the New York Academy of Sciences.

[72]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[73]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[74]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[75]  P. Laird,et al.  Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.

[76]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[77]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[78]  J. Issa,et al.  Epigenetics in colorectal cancer. , 2002, Current opinion in gastroenterology.

[79]  Robert A Copeland,et al.  Annals of the New York Academy of Sciences Targeting Epigenetic Regulators for Cancer Therapy , 2022 .